ISRCTN10975080已完成不适用
Tolerability and safety of capsaicinoids from capsicum extract (Capsimax®): a randomized, double-blind, placebo-controlled, dose-finding, adaptive-design study
OmniActive Health Technologies Inc. (USA)0 个研究点目标入组 12 人开始时间: 2015年6月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
2016 results in: http://www.ncbi.nlm.nih.gov/pubmed/27066073
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Healthy female subjects between 25 and 55 years of age
- •2. Body mass index (BMI) between 25 and 34.9 kg/m2 (inclusive)
- •3. Judged by the Investigator to be in general good health on the basis of medical history
- •4. Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator
- •5. Subject agrees to all study visits and procedures
- •6. Subject agrees to travel to DEXA facility location
- •7. Sedentary lifestyle: not being physically active greater than 3 days/week for 20 minutes each time for the previous 6 months, and not participating in regular resistance exercise
排除标准
- •1. Regular ingestion of chili peppers (raw or powdered form), black pepper, or ginger, or foods known to contain chili peppers, black pepper or ginger more than 3 times per week on average
- •2. Known allergy to chili pepper
- •3. Known allergy to any foods
- •4. Consumption of >3 servings per day of caffeine containing beverages
- •5. Any significant GI condition that would potentially interfere with the evaluation of the study product including but not limited to inflammatory bowel disease (Ulcerative Colitis or Crohn’s), history of frequent diarrhea, history of surgery for weight loss (including gastric bypass or lapband), history of perforation of the stomach or intestines, gastroparesis, clinically important lactose intolerance.
- •6. Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, hematologic, or biliary disorder
- •7. History or presence of cancer in the prior two years, except for non-melanoma skin cancer
- •8. Recent history of (within 12 months) or strong potential for alcohol or substance abuse
- •9. Participation in a clinical study with exposure to any non-registered drug product within 30 days prior
- •10. Individual has a condition the Investigator believes would interfere with her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk
- •11. Diabetes requiring medication
- •12. Untreated or unstable Hypothyroidism
- •13. Weight loss or gain of at least 10 pounds in the last 3 months
- •14. Participation in a formal weight loss program or diet plan in the last 3 months
- •15. Clinically significant abnormal Physical Examination
- •16. Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders
- •17. Central Neurological disorders including but not limited to Spinal cord injuries, multiple sclerosis, Parkinson disease
- •18. Pregnant, lactating, or unwilling to use adequate contraception during the duration of the study
- •19. Currently taking antacids or acid-blocking medications
- •20. Currently taking anti-coagulant medications (including but not limited to aspirin, ticlid, heparin, and Coumadin)
- •21. Currently taking MAO-Inhibitors
- •22. Currently taking herbal products or dietary supplements – subjects who are willing to wash out of these products may be included after a 2 week washout period
研究者
相似试验
已完成
不适用
ClUDo: The Clinical Utility of Capsaicin Dose Response Curves to Discriminate Cough Hyper-responsivenessChronic coughRespiratoryISRCTN23684347niversity Hospital of South Manchester NHS Foundation Trust (UK)200
已完成
1 期
Study of Capsaicin Patch for the Management of Peripheral Neuropathic PainPeripheral Nerve InjuryPostherpetic NeuralgiaNCT02228928Samyang Biopharmaceuticals Corporation60
撤回
不适用
Capsaicinoid Ingestion, Human Metabolism and ExerciseMetabolismNCT02139852University of Prince Edward Island
撤回
不适用
Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)MetabolismExerciseNCT02138630University of Prince Edward Island
已完成
不适用
Validation of the capsaicin (1%) sensitization model in the context of the PainCart test batterypainNeuropathic painNL-OMON45379Centre for Human Drug Research38